These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 15510202)

  • 1. Analysis of efficacy and toxicity of thalidomide in 122 patients with multiple myeloma: response of soft-tissue plasmacytomas.
    Wu KL; Helgason HH; van der Holt B; Wijermans PW; Lokhorst HM; Smit WM; Sonneveld P
    Leukemia; 2005 Jan; 19(1):143-5. PubMed ID: 15510202
    [No Abstract]   [Full Text] [Related]  

  • 2. Extramedullary multiple myeloma escapes the effect of thalidomide.
    Rosiñol L; Cibeira MT; Bladé J; Esteve J; Aymerich M; Rozman M; Segarra M; Cid MC; Filella X; Montserrat E
    Haematologica; 2004 Jul; 89(7):832-6. PubMed ID: 15257935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%].
    Wu KL; Schaafsma MR; Lokhorst HM; Wijermans PW; van der Holt B; Sonneveld P
    Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1445-8. PubMed ID: 12190011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide in refractory and relapsing multiple myeloma.
    Bladé J; Esteve J; Rosiñol L; Perales M; Montoto S; Tuset M; Montserrat E
    Semin Oncol; 2001 Dec; 28(6):588-92. PubMed ID: 11740814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study.
    Feyler S; Rawstron A; Jackson G; Snowden JA; Cocks K; Johnson RJ
    Br J Haematol; 2007 Nov; 139(3):429-33. PubMed ID: 17910633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects.
    Corso A; Zappasodi P; Barbarano L; Petrucci MT; Palumbo A; Caravita T; Mangiacavalli S; Cafro AM; Varettoni M; Gay F; Morra E; Lazzarino M
    Leuk Res; 2009 Sep; 33(9):e145-9. PubMed ID: 19375164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low efficacy of thalidomide in improving response after induction in multiple myeloma patients who are candidates for high-dose therapy.
    Corso A; Mangiacavalli S; Barbarano L; Montalbetti L; Mazzone A; Fava S; Varettoni M; Zappasodi P; Morra E; Lazzarino M
    Leuk Res; 2008 Jul; 32(7):1085-90. PubMed ID: 18096226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thalidomide in consecutive multiple myeloma patients: single-center analysis on practical aspects, efficacy, side effects and prognostic factors with lower thalidomide doses.
    Haas PS; Denz U; Ihorst G; Engelhardt M
    Eur J Haematol; 2008 Apr; 80(4):303-9. PubMed ID: 18182082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients.
    Guglielmelli T; Bringhen S; Rrodhe S; Gay F; Cavallo F; Berruti A; Montefusco V; Piro E; Benevolo G; Petrucci MT; Caravita T; Offidani M; Corradini P; Boccadoro M; Saglio G; Palumbo A
    Eur J Cancer; 2011 Apr; 47(6):814-8. PubMed ID: 21334196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma.
    Galli M; Elice F; Crippa C; Comotti B; Rodeghiero F; Barbui T
    Haematologica; 2004 Sep; 89(9):1141-2. PubMed ID: 15377478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Reported use of thalidomide in multiple myeloma: presentation of problems in the Thaled® outpatient department].
    Aimono Y; Sato W; Otani E; Isa S; Sawahata T; Onozaki M; Saito Y; Ebata S; Aoyama Y; Hakozaki M; Suzuki M; Kudo D; Monma Y; Chikatsu N; Shinagawa A
    Gan To Kagaku Ryoho; 2011 Dec; 38(13):2579-84. PubMed ID: 22189222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of thalidomide in refractory multiple myeloma.
    Singhal S; Mehta J; Desikan R; Ayers D; Roberson P; Eddlemon P; Munshi N; Anaissie E; Wilson C; Dhodapkar M; Zeddis J; Barlogie B
    N Engl J Med; 1999 Nov; 341(21):1565-71. PubMed ID: 10564685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of thalidomide in the treatment of multiple myeloma.
    Warzocha K; Kraj M; Pogłód R; Szpila T; Mendek-Czajkowska E; Chełstowska M; Tronina RH
    Acta Pol Pharm; 2008; 65(6):771-4. PubMed ID: 19172865
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical assessment of bortezomib for multiple myeloma in comparison with thalidomide.
    Satoh M; Oguro R; Yamanaka C; Takada K; Matsuura Y; Akiba T; Aotsuka N; Tani Y; Wakita H
    J Pharm Pharm Sci; 2011; 14(1):78-89. PubMed ID: 21501555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thromboembolism in patients on thalidomide for myeloma.
    Bowcock SJ; Rassam SM; Ward SM; Turner JT; Laffan M
    Hematology; 2002 Feb; 7(1):51-3. PubMed ID: 12171777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thalidomide treatment of patients with refractory myeloma in the institutes participating in the Japan Myeloma Study Group].
    Murakami H; Handa H; Imai K; Kanakura Y; Kosaka M; Sawamura M; Shimazaki C; Suzuki K; Ishii A; Takagi T; Taniwaki M; Togawa A; Hata H; Wakayama T; Takatsuki K;
    Rinsho Ketsueki; 2004 Jun; 45(6):468-72. PubMed ID: 15287523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
    Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
    J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thalidomide induced impotence in male hematology patients: a common but ignored complication?
    Murphy PT; O'Donnell JR
    Haematologica; 2007 Oct; 92(10):1440. PubMed ID: 18024384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early response predicts thalidomide efficiency in patients with advanced multiple myeloma.
    Waage A; Gimsing P; Juliusson G; Turesson I; Gulbrandsen N; Eriksson T; Hjorth M; Nielsen JL; Lenhoff S; Westin J; Wislöff F;
    Br J Haematol; 2004 Apr; 125(2):149-55. PubMed ID: 15059136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation.
    Biagi JJ; Mileshkin L; Grigg AP; Westerman DW; Prince HM
    Bone Marrow Transplant; 2001 Dec; 28(12):1145-50. PubMed ID: 11803357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.